Biotech Specialty Pharma

Senesco Technologies, Inc

721 Route 202/206, Suite 130
Bridgewater, NJ 08807 United States
Click for website

Research Sector Biotech Specialty Pharma

Summary Description Proprietary gene-based technology for use in human therapeutic and agricultural applications.

Management Harlan Waksal, M.D., Chairman; Jack van Hulst, CEO; John Thompson, Ph.D., Executive VP of R&D and CSO; Joel Brooks, CFO; Sascha Fedyszyn, VP of Corporate Development; Richard Dondero, VP of R&D.

Click here for Financial Data
Keywords: genomics, cancer, glaucoma, heart disease, SNT


Updated: Apr. 01, 2013


Senesco Technologies is a U.S. biotechnology company, developing its proprietary eiF5A (Factor 5A) gene technology as a potential treatment for both oncology and inflammatory conditions. Senesco's p......view more

Products / Services

Senesco has designed a drug called SNS-01 that is specifically targeted to multiple myeloma, its first clinical target. SNS-01 contains three parts: a DNA plasmid which increases the lysine form of Fa......view more

Technology / Differentiation

Senesco's proprietary technology is based on a gene called Factor 5A. Factor 5A has two forms, the lysine and hypusine forms, which act in concert as a regulatory switch. If the lysine form of Factor ...view more


Preclinical testing of SNS-01. Senesco's near term objectives are finalization of the formulation of SNS-01, a definitive toxicity study in larger animals to ensure safety and the approval of the Inve...view more